Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q99757
UPID:
THIOM_HUMAN
Alternative names:
Thioredoxin-2
Alternative UPACC:
Q99757; Q5JZA0; Q6FH60; Q9UH29
Background:
Thioredoxin, mitochondrial, also known as Thioredoxin-2, plays a crucial role in maintaining mitochondrial reactive oxygen species homeostasis, apoptosis regulation, and cell viability. Its unique dithiol-reducing activity is essential for cellular redox balance.
Therapeutic significance:
Linked to Combined oxidative phosphorylation deficiency 29, a severe neurodegenerative disorder, understanding Thioredoxin-2's function could pave the way for novel therapeutic approaches targeting mitochondrial dysfunctions.